Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet Oncology · Published 2026-07-27 · DOI 10.1016/s1470-2045(26)00132-4

Free full text

Authors (54)

David Sebag-Montefiore, Richard Adams, Simon Gollins, Leslie M Samuel, Robert Glynne-Jones, Robert Harte, Nicholas West, Philip Quirke, Arthur Sun Myint, Simon Bach, Philip Parsons, Amandeep Singh Dhadda, Nicholas Brown, Gina Brown, Mark Harrison, Rhydian Maggs, Rubina Begum, Elizabeth Chang, Allan Hackshaw, Andre Lopes, Stephen Falk, Vivek Misra, Andrew Weaver, Amir Montazeri, Susan Clenton, Zuzana Stokes, Jeffrey Summers, Susan Cleator, Rhydian Maggs, Ian Geh, Catherine Jephcott, Fawzi Adab, Mark Churn, Lucinda Melcher, Kathryn Wright, David Whillis, Sharadah Essapen, Alec McDonald, Emma Gray, Kim Benstead, Andrew Gaya, Duncan Gilbert, Bruce Sizer, Albert Edwards, Craig Macmillan, Sherif Raouf, Melanie Osborne, Catriona McLean, Margaret King, Abel Zachariah, Shabbir Susnerwala, Sarah Gwynne, Andrew Bateman, David Tsang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Sebag-Montefiore, D., Adams, R., Gollins, S., et al. (2026). Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00132-4

Related articles